Navigation Links
Brennen Medical Announces Sale of XenMatrix(R)
Date:9/21/2009

ST. PAUL, Minn., Sept. 21 /PRNewswire/ -- Brennen Medical, LLC, a leader in biomaterials technology, announces the sale of its XenMatrix(R) device to Davol Inc., a subsidiary of C.R. Bard, Inc. The agreement provides Davol with the worldwide rights and related assets of the hernia products business of Brennen Medical, LLC. This acquisition includes technology for a non crosslinked xenograft device for use in soft tissue repair including hernia and abdominal wall reconstruction.

XenMatrix employs a proprietary technology that maintains an acellular structurally intact, non crosslinked porcine dermal matrix for enhanced biocompatibility in host tissue. This dermal matrix supports revascularization, remodeling and regeneration for abdominal wall and hernia repairs. Recently published data in the American Journal of Surgery from the Brigham and Women's Hospital studied the use of XenMatrix in complex abdominal wall defects and reported a 93% success rate with over 16 months follow-up.

"We are extremely pleased with the successful clinical outcomes of XenMatrix. Now with the acquisition by C.R. Bard, this product will reach a far greater number of patients worldwide, who will truly benefit from this device," said Phillip Lawin, PhD, President of Brennen Medical.

About Brennen Medical, LLC

Brennen Medical is a world leader providing biologic porcine xenograft for use in plastic reconstructive, general surgery, burn, trauma, wound, urogynecological and orthopedic soft tissue repair procedures. Demonstrated to be effective, surgeons have used Brennen's proprietary porcine technologies for over 40 years. Mediskin(R) and EZ Derm(R), XenMatrix and DermMatrix(R) provide the basis for innovation and quality to guide the Company's initiatives for a growing biosurgical market. Based in St. Paul, MN and privately held, the products are sold through a direct sales force and through partnerships with major medical device companies. In addition to porcine, Brennen also markets a line of products containing oat beta glucan, a natural complex carbohydrate successfully used to manage burn and chronic wounds.

XenMatrix and DermMatrix are trademarks and/or registered trademarks of C. R. Bard, Inc. or an affiliate.

Mediskin and EZ Derm are registered trademarks of Brennen Medical, LLC.


'/>"/>
SOURCE Brennen Medical, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... of Financial Services (NYS DFS) cybersecurity regulations have transitioned into full ... insurance organizations operating in the state (“Covered Entities”) to conduct an annual, ...
(Date:9/18/2017)... (PRWEB) , ... September 18, 2017 , ... ... has announced the move of the SPIE Digital Library ( http://www.spiedigitallibrary.org ) on ... SPIE to create an improved user experience and incorporate a number of enhancements ...
(Date:9/17/2017)... ... September 17, 2017 , ... ... South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New ... the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... and biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, ... world’s most progressive clinical research leaders for best practice case studies, keynote presentations, ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):